Covid Studies

To share information, log in to CLIC site and submit any COVID-19 research that is occurring at your institution.
Title Clinicaltrials.gov Status Current Study Phase Current Study Status Sponsor Study Type Treatments and Interventions Updated date
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults Submitted to clinicaltrials.gov Phase 3 Recruiting National Institute of Allergy and Infectious Diseases Clinical Trial Drug: Remdesivir Thu, 04/23/2020 - 07:36
A PHASE II, OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY TO INVESTIGATE THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY, AND EFFICACY OF 8 mg/kg OR 4 mg/kg INTRAVENOUS TOCILIZUMAB IN PATIENTS WITH MODERATE TO SEVERE COVID-19 PNEUMONIA Submitted to clinicaltrials.gov Phase 2 Recruiting Other Clinical Trial 8 mg/kg OR 4 mg/kg INTRAVENOUS TOCILIZUMAB Fri, 05/22/2020 - 16:54
A Randomized Controlled Open-Label Study of CM4620 Injectable Emulsion in Patients with Severe COVID-19 Pneumonia Submitted to clinicaltrials.gov Phase 2 Recruiting Other Clinical Trial CM4620 Mon, 05/11/2020 - 07:18
Are you a healthcare worker that comes in contact with patients? Pre-clinicaltrials.gov Not a Clinical Trial Recruiting Oregon Health and Science University Observational Study (no biological samples needed and no intervention) none Tue, 04/28/2020 - 05:18
DETECT Study Submitted to clinicaltrials.gov N/A Recruiting Observational Study (no biological samples needed and no intervention) Observational study, no treatment or intervention Fri, 04/24/2020 - 17:26
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 Submitted to clinicaltrials.gov Phase 2 Recruiting Other Clinical Trial Sarilumab Mon, 05/11/2020 - 07:17
Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19 Submitted to clinicaltrials.gov N/A Recruiting Medical University Of South Carolina Clinical Trial Convalescent Plasma Tue, 05/05/2020 - 10:57
GS-US-540-5773 - A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Severe COVID-19 Submitted to clinicaltrials.gov Phase 3 Recruiting Other Clinical Trial Drug: Remdesivir Mon, 05/11/2020 - 07:17
GS-US-540-5774 - A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment Submitted to clinicaltrials.gov Phase 3 Recruiting Other Clinical Trial Drug: Remdesivir Mon, 05/11/2020 - 07:18
Mavrilimumab to reduce progression of acute respiratory failure in patients with severe COVID-19 pneumonia and systemic hyper-inflammation Pre-clinicaltrials.gov Phase 2 Not yet recruiting Other Clinical Trial Mavrilimumab or placebo Mon, 05/11/2020 - 07:18
Observational COVID-19 Immunity Study Pre-clinicaltrials.gov Not a Clinical Trial Recruiting National Institute of Allergy and Infectious Diseases Clinical Research Procedure: Blood draw, Procedure: Nasal swab Mon, 04/20/2020 - 18:28
Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease Submitted to clinicaltrials.gov Phase 2 - Phase 3 Recruiting National Institutes of Health Clinical Trial hydroxychloroquine or placebo Tue, 05/05/2020 - 10:57
Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease Submitted to clinicaltrials.gov Phase 3 Recruiting Other Clinical Trial Drug: Hydroxychloroquine Mon, 05/11/2020 - 07:17
Phase 3 multicenter, randomized, double-blind, placebo controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID) Submitted to clinicaltrials.gov Phase 3 Recruiting Other Clinical Trial Canakinumab or placebo Mon, 05/11/2020 - 07:17
Pre Exposure Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19 infection Pre-clinicaltrials.gov Phase 3 Not yet recruiting Clinical Trial Hydroxychloroquine- oral administration Wed, 04/15/2020 - 17:30
Rapid In-Home SARS-CoV-2 IgG Antibody Testing to Assess Community Level Immunity in HealthCare Workers Working in High Risk Exposure Settings Pre-clinicaltrials.gov Not a Clinical Trial Recruiting Medical University Of South Carolina Clinical Research Finger Stick Wed, 04/29/2020 - 10:25
Safety and Efficacy of Baricitinib for COVID-19 Submitted to clinicaltrials.gov Phase 2 - Phase 3 Not yet recruiting University Of Colorado Denver Clinical Trial Subjects will receive a 2 mg oral dose of baricitinib daily for 14 days. Thu, 05/07/2020 - 10:18
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection (COVID-19) Submitted to clinicaltrials.gov Phase 1 Recruiting National Institute of Allergy and Infectious Diseases Clinical Trial Biological: mRNA-1273 Fri, 04/24/2020 - 18:44
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) Submitted to clinicaltrials.gov Phase 3 Recruiting Other Clinical Trial Drug: Remdesivir Drug: Standard of Care Thu, 05/07/2020 - 10:15
Trial of the combination of Hydroxychloroquine and Azithromycin in the treatment of hospitalized patients with moderate or severe COVID-19 infection Pre-clinicaltrials.gov Phase 3 Recruiting Clinical Trial Drug: Hydroxychloroquine, Drug: Azithromycin Wed, 04/15/2020 - 10:30